Company: SPRB
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001193125-25-274234
Chunk: 12

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 12
---
, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

•If the market opportunities for TA-ERT, tildacerfont, SPR202 and our other current and future product candidates are smaller than we believe they are, our future revenue may be adversely affected and our business may suffer.

•We currently have no marketing and sales organization and have yet to commercialize a product. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell TA-ERT, tildacerfont, SPR202 and our other current and future product candidates, we may not be able to generate product revenues.

•Unfavorable U.S. and global economic and geopolitical conditions could adversely affect our business, financial condition or results of operations.

•International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.

•We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.